NasdaqGS - Delayed Quote • USD Amyris, Inc. (AMRS) Follow 0.0500 0.0000 (0.00%) As of April 4 at 4:00 PM EDT. Market Open. All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Retail investors flock to penny stocks WeWork, Amyris, Proterra WeWork, a prized startup just four years ago but now a micro-cap, and other penny stocks such as Amyris and Proterra are the latest focus of speculative bets from retail traders, with shares of the financially struggling firms rising in strong trading volume after hitting record lows this week. The three penny stocks, up in the range of 40% to 120%, were the most actively traded U.S. shares at 10:45 a.m. ET on Friday. Amyris and WeWork were the second and third most traded stocks by retail investors, respectively, while Proterra was twelfth on the list at 10 a.m. ET, according to J.P.Morgan data. Biotech firm Amyris files for bankruptcy in US Amyris said it has secured a $190 million financing commitment to support day-to-day operations, adding that its entities outside the U.S. are not included in the bankruptcy proceedings. In a filing with the Delaware bankruptcy court, the company listed estimated assets in the range of $500 million to $1 billion and liabilities in the range of $1 billon to $10 billion. "Restructuring is intended to improve the Company's cost structure, capital structure, and liquidity position while streamlining Amyris' business portfolio to focus on its core competencies in R&D...," the company said. UPDATE 1-Biotech firm Amyris files for bankruptcy in US Biotech firm Amyris Inc on Wednesday said it has filed for Chapter 11 bankruptcy in a U.S. court and is planning to sell its consumer brands to improve the company's liquidity position. Amyris said it has secured a $190 million financing commitment to support day-to-day operations, adding that its entities outside the U.S. are not included in the bankruptcy proceedings. In a filing with the Delaware bankruptcy court, the company listed estimated assets in the range of $500 million to $1 billion and liabilities in the range of $1 billon to $10 billion. AMYRIS ANNOUNCES OPERATIONAL AND FINANCIAL RESTRUCTURING TO ADVANCE STRATEGIC TRANSFORMATION Amyris, Inc. (Nasdaq: AMRS) ("Amyris" or the "Company"), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, today announced that it is moving forward with an operational and financial restructuring to further advance its ongoing strategic transformation and position the Company for long-term success. 7 Biotech Stocks to Sell in July Biotech may be a great sector for risk-seeking investors to find opportunity. That said, for every biotech stock worth buying, there are plenty that fit into the “biotech stocks to sell” category. For one, while biotechs are some of the riskier stocks out there, that doesn’t mean all of them offer the possibility of outsized rewards. Plenty of names in this category have massive downside risk, while at the same time offering questionable upside potential. Other biotechs may have tremendous upsid Is It Time to Buy This Year's Worst-Performing Growth Stocks? Ready to make sense of the market's laggards? The share prices of these high-octane growth stocks are falling in 2023, so it might be time to bet on rebounds -- but only some of them. The past five years for Amyris (NASDAQ:AMRS) investors has not been profitable We're definitely into long term investing, but some companies are simply bad investments over any time frame. We don't... AMYRIS ANNOUNCES CEO TRANSITION AND GLOBAL REDUCTION IN FORCE Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, today announced that John Melo has resigned from his role as President & Chief Executive Officer and a member of the Board of Directors, effective immediately. The Company's Board of Directors has appointed Han Kieftenbeld as Interim Chief Executive Officer. Mr. Kieftenbeld will remai AMYRIS INITIATES STRATEGIC TRANSFORMATION PROGRAM AND SECURES FUNDING Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-MarketTM technology platform and clean beauty consumer brands, today announced that its Board of Directors has engaged the Business Recovery Services unit of PricewaterhouseCoopers ("PwC") and established a subcommittee of the Board (the "Restructuring Committee"), made up of three independent directors, working with Management, to execute on a Amyris (AMRS) Q1 Earnings In Line, Revenues Beat Estimates Amyris (AMRS) sees lower sales in its Consumer and Technology Access segments in the first quarter. Individual investors account for 38% of Amyris, Inc.'s (NASDAQ:AMRS) ownership, while institutions account for 31% Key Insights Amyris' significant individual investors ownership suggests that the key decisions are influenced by... AMYRIS COMPLETES LICENSE FOR SUPPLY OF SUSTAINABLE SQUALENE EMERYVILLE, Calif., May 19, 2023 Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, today announced that it has signed an exclusive license agreement with British specialty chemicals company Croda International Plc, ("Croda") for the supply of sustainable squalene. Amyris, Inc. (AMRS) Reports Q1 Loss, Tops Revenue Estimates Amyris, Inc. (AMRS) delivered earnings and revenue surprises of 0% and 0.06%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock? AMYRIS, INC. REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-MarketTM technology platform and clean beauty consumer brands, today announced financial results for the first quarter ended March 31, 2023. Analysts Estimate Mativ Holdings (MATV) to Report a Decline in Earnings: What to Look Out for Mativ Holdings (MATV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. Amyris, Inc. (AMRS) Expected to Beat Earnings Estimates: Should You Buy? Amyris, Inc. (AMRS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. AMYRIS TO HOST FIRST QUARTER 2023 FINANCIAL RESULTS CONFERENCE CALL ON MAY 9 Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, today announced that it will issue its financial results for the first quarter ended March 31, 2023, on the afternoon of Tuesday, May 9, 2023, after closing of the financial markets.
